or Try an Advanced Search...

    Technical Analysis for BNTC - Benitec Biopharma Limited

    Grade Last Price % Change Price Change
    C 10.40 -0.38% -0.04
    BNTC closed down 0.38 percent on Thursday, November 14, 2024, on 1.43 times normal volume.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical BNTC trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    Gapped Up Strength 0.00%
    Fell Below 20 DMA Bearish -0.38%
    1,2,3 Pullback Bullish Bullish Swing Setup -0.38%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.38%
    Bollinger Band Squeeze Range Contraction -0.38%
    Inside Day Range Contraction -0.38%
    20 DMA Support Bullish -4.32%
    Hammer Candlestick Bullish -4.32%
    1,2,3 Pullback Bullish Bullish Swing Setup -4.32%
    Older End-of-Day Signals for BNTC ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance about 15 hours ago
    Fell Below Previous Day's Low about 15 hours ago
    Fell Below Lower Bollinger Band about 16 hours ago
    Down 1% about 16 hours ago
    Up 1% about 16 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BNTC Chart by TradingView
    Basic chart:

    Profile

    Benitec Biopharma Limited Description

    Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Biotechnology Biopharmaceutical Biology Pain Genetics Chemotherapy Small Cell Lung Cancer Hepatitis B Macular Degeneration Genetic Engineering Dystrophy Gene Expression Muscular Dystrophy Hepatitis C Wet Age Related Macular Degeneration Huntington's Disease HIV/Aids RNA Ai Technology Retinitis Rna Interference Clinical Applications Retinitis Pigmentosa Chronic And Life Threatening Conditions Gene Silencing Oculopharyngeal Muscular Dystrophy

    Is BNTC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 Benitec GAAP EPS of -$0.48
    Nov 14 Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
    Nov 4 Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
    Oct 17 Benitec Biopharma: OPMD Program Continues To Advance With Catalysts
    Oct 16 Benitec started at outperform by Oppenheimer on gene therapy potential
    Oct 14 Benitec Biopharma Announces Updated Investor Webcast Information
    Oct 12 Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
    Oct 9 Benitec Biopharma's BB-301: Potential In OPMD But Still Too Early Stages
    Oct 1 Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc
    Sep 28 Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans
    See more BNTC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.89
    52 Week Low 2.69
    Average Volume 34,531
    200-Day Moving Average 7.75
    50-Day Moving Average 9.87
    20-Day Moving Average 10.74
    10-Day Moving Average 10.63
    Average True Range 0.60
    RSI (14) 49.49
    ADX 34.2
    +DI 17.94
    -DI 11.54
    Chandelier Exit (Long, 3 ATRs) 9.75
    Chandelier Exit (Short, 3 ATRs) 11.60
    Upper Bollinger Bands 11.27
    Lower Bollinger Band 10.22
    Percent B (%b) 0.17
    BandWidth 9.81
    MACD Line 0.15
    MACD Signal Line 0.24
    MACD Histogram -0.0851
    Fundamentals Value
    Market Cap 26.75 Million
    Num Shares 2.57 Million
    EPS -234.82
    Price-to-Earnings (P/E) Ratio -0.04
    Price-to-Sales 98.27
    Price-to-Book 0.33
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.98
    Resistance 3 (R3) 10.99 10.81 10.88
    Resistance 2 (R2) 10.81 10.67 10.81 10.85
    Resistance 1 (R1) 10.61 10.58 10.52 10.59 10.82
    Pivot Point 10.43 10.43 10.38 10.42 10.43
    Support 1 (S1) 10.22 10.28 10.13 10.21 9.98
    Support 2 (S2) 10.04 10.19 10.04 9.95
    Support 3 (S3) 9.84 10.04 9.92
    Support 4 (S4) 9.82